The Sequencing of Trabectedin with other Agents is also Worth Examining.
Authors : Ravin Ratan / Shreyaskumar R. Patel .
Sarcoma (SH Okuno, Section Editor) /// First Online: 22 May 2017 .
Trabectedin and eribulin are two agents that have been recently approved for the treatment of specific soft tissue sarcoma subtypes.
They have proved to be a much-needed line of additional treatment for patients with these rare tumors, but their activity remains admittedly modest in most cases.
Further exploitation of these novel agents is likely to require a more granular understanding of the salient mechanisms of action.
For example, if as some studies suggest, eribulin derives its benefit from restructuring of tumor vasculature to improve efficacy of subsequent lines of therapy, then patients may benefit from its use earlier in the treatment pathway.
The sequencing of trabectedin with other agents is also worth examining. In a disease like myxoid liposarcoma, consideration should be given to using trabectedin before other salvage regimens like gemcitabine and docetaxel, given its tolerability and excellent efficacy against this sarcoma subtype.
Also, to be further investigated is the use of trabectedin in sarcoma subtypes which were excluded from the phase III study, but in which activity has been documented in earlier trials and subsequent reports. Combinations of trabectedin with other agents, particularly doxorubicin, have been explored, but the data to date do not support the routine use of these regimens.
YONDELIS was originally made from sea squirts, or the marine organism Ecteinascidia turbinata. It works by stopping the abnormal multiplication of cancer cells within the body that would otherwise spread, destroying nearby tissues. It does this by binding to and damaging the DNA in cancer cells, causing the cells to die.